Vistagen

Vistagen Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Vistagen, Mental Health Service, 343 Allerton Avenue, South San Francisco, CA.

Vistagen is a late clinical-stage company leveraging its pioneering neuroscience & deep understanding of nose-to-brain neurocircuitry to develop and commercialize a broad and diverse pipeline of intranasal product candidates called pherines (Nasdaq: VTGN)

Vistagen today announced that the Company’s clinical program for fasedienol nasal spray for the acute treatment of socia...
06/09/2026

Vistagen today announced that the Company’s clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the minimum patient exposures as recommended under ICH E1, the international regulatory standard governing safety database exposure recommendations for drugs intended for long-term treatment (chronic or repeated intermittent use for longer than 6 months) of non-life-threatening conditions. Read more: https://bit.ly/4uiGCiN

Vistagen will participate in the Jefferies 2026 Global Healthcare conference being held June 2-4, 2026, in New York City...
05/27/2026

Vistagen will participate in the Jefferies 2026 Global Healthcare conference being held June 2-4, 2026, in New York City. The Company will host one-on-one meetings with institutional investors during the conference. For details: https://bit.ly/4u4qscX

Vistagen today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18,...
05/19/2026

Vistagen today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026. Read more: https://bit.ly/4eS7xhz

Vistagen President and CEO, Shawn Singh, will participate in a fireside chat at the RBC Capital Markets Global Healthcar...
05/14/2026

Vistagen President and CEO, Shawn Singh, will participate in a fireside chat at the RBC Capital Markets Global Healthcare conference on Wednesday, May 20 at 2:35 p.m. ET. The Company will also host one-on-one meetings during the conference. For details: https://bit.ly/4nqa1po

05/12/2026

Shawn Singh, President and Chief Executive Officer of Vistagen, comments on the positive preliminary data from the ongoing open-label extension (OLE) portion of its PALISADE-3 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder. For more details, visit: https://bit.ly/4uFxIfM

In the ongoing OLE portion of PALISADE-3, preliminary positive data demonstrated clinically relevant improvement in soci...
05/12/2026

In the ongoing OLE portion of PALISADE-3, preliminary positive data demonstrated clinically relevant improvement in social anxiety over time was observed on both clinician-administered and patient-reported scales over four months. Read more on the preliminary data: https://bit.ly/4uFxIfM

Vistagen today announced preliminary positive data from the ongoing open-label extension (OLE) portion of its PALISADE-3...
05/12/2026

Vistagen today announced preliminary positive data from the ongoing open-label extension (OLE) portion of its PALISADE-3 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder. Fasedienol nasal spray has been well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use in daily life for up to 12 months. Read more: https://bit.ly/4uFxIfM

Vistagen today announced that the last patient has completed the last visit in the randomized, double-blind, placebo-con...
05/08/2026

Vistagen today announced that the last patient has completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Company’s Phase 3 clinical trial evaluating fasedienol nasal spray for the acute treatment of social anxiety disorder. Topline results for the randomized portion of PALISADE-4 are expected in the first half of 2026. The open label extension (OLE) portion of the PALISADE-4 study remains ongoing. Read more: https://bit.ly/4dwTBbv

Vistagen today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) under ...
04/22/2026

Vistagen today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) under its U.S. Investigational New Drug (IND) application for refisolone nasal spray, the Company’s non-hormonal, non-systemic product candidate in Phase 2 development for treatment of moderate to severe vasomotor symptoms (VMS) (also known as “hot flashes”) due to menopause. Read more: https://bit.ly/4vAeHwG

Tomorrow, March 17th at 9:00 AM ET, Vistagen CEO Shawn Singh will participate in a fireside chat and one-on-one meetings...
03/16/2026

Tomorrow, March 17th at 9:00 AM ET, Vistagen CEO Shawn Singh will participate in a fireside chat and one-on-one meetings at the Stifel 2026 Virtual CNS Forum. Watch the live webcast here: https://bit.ly/4l8ylen

Address

343 Allerton Avenue
South San Francisco, CA
94080

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm
Saturday 9am - 5pm
Sunday 9am - 5pm

Telephone

+16505773600

Website

Alerts

Be the first to know and let us send you an email when Vistagen posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category